These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16353143)

  • 1. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
    Visser J; van Baarle D; Hoogeboom BN; Reesink N; Klip H; Schuuring E; Nijhuis E; Pawlita M; Bungener L; de Vries-Idema J; Nijman H; Miedema F; Daemen T; van der Zee A
    Int J Cancer; 2006 May; 118(10):2529-37. PubMed ID: 16353143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
    J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
    Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
    Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
    Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
    Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
    Luxton JC; Rowe AJ; Cridland JC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
    Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
    Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
    Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
    Roman LD; Wilczynski S; Muderspach LI; Burnett AF; O'Meara A; Brinkman JA; Kast WM; Facio G; Felix JC; Aldana M; Weber JS
    Gynecol Oncol; 2007 Sep; 106(3):558-66. PubMed ID: 17631950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.
    Visser J; Nijman HW; Hoogenboom BN; Jager P; van Baarle D; Schuuring E; Abdulahad W; Miedema F; van der Zee AG; Daemen T
    Clin Exp Immunol; 2007 Nov; 150(2):199-209. PubMed ID: 17937675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Doekhie FS; Remmink AJ; Helmerhorst TJ; Verheijen RH; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    Cancer Res; 1998 Apr; 58(8):1700-6. PubMed ID: 9563486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.